Mesoblast (ASX:MSB) Shares Fall Today: What Is Keeping the Cell Therapy Stock on Investors' Radar?

Sonal Goyal

06 November 2026 06:09 PM AEDT

Mesoblast (ASX:MSB) Shares Fall Today: What Is Keeping the Cell Therapy Stock on Investors' Radar?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Mesoblast (ASX:MSB) traded at A$2.03 during the 6 November 2026 session, down 6.45%, the largest fall among the stocks in this series.
Its quarterly activity report for the period to 30 September 2026 reported a 44% increase in net revenues.
Net operational cash spend improved 86% compared with the prior year period.

Mesoblast (ASX:MSB) shares were quoted at A$2.03 during the 6 November 2026 trading session, down 6.45%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 28 and 29 October 2026 activity report. Mesoblast develops allogeneic cellular medicines for inflammatory diseases and is listed on the ASX and Nasdaq.

Latest Developments

Quarterly Activity Report for the Quarter Ended 30 September 2026 (released 28 and 29 October 2026)

Mesoblast reported a 44% increase in net revenues and an 86% improvement in net operational cash spend compared with the prior year period. It completed all patient treatment in the pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L for inflammatory chronic low back pain. It also reported a positive meeting with the FDA about a planned Biologics License Application for preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients with a left ventricular assist device.

About the Company

Mesoblast is an ASX and Nasdaq-listed cell therapy company headquartered in Melbourne with a US presence. Its releases are issued in both New York and Melbourne time.

Business Overview

Mesoblast develops allogeneic cellular medicines, including rexlemestrocel-L, for inflammatory and cardiovascular conditions. Its commercial Revenue and development progress are reported in its quarterly activity reports.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Cell therapy companies carry clinical, regulatory and funding risks, and their share prices can be sensitive to trial results and regulatory communication.

Risks to Watch

The planned BLA filing depends on regulatory review, and the Phase 3 chronic low back pain results are not included in the activity report. Cash spend and the timing of commercial revenue remain relevant to funding needs.

Catalysts on Watch

Investors may follow Phase 3 results for chronic low back pain, the BLA filing timetable and the next quarterly activity report.

Final Takeaways

Mesoblast (ASX:MSB) traded lower on 6 November 2026, with the largest percentage fall among the stocks in this series. Its quarterly report, released on 28 and 29 October 2026, is dated separately from the session.

FAQs

Q: What was the MSB share price on 6 November 2026?

A: Mesoblast shares were quoted at A$2.03 during the trading session, down 6.45%.

Q: What was the net revenue increase?

A: 44%, per the quarterly activity report.

Q: What trial was completed?

A: Patient treatment in the Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain.

Q: What did the FDA meeting cover?

A: A planned BLA filing for preventing GI bleeding in LVAD patients with end-stage heart failure.

Q: Is the session move linked to the report?

A: No. The report was released on 28 and 29 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.